Prognostic role of serum cytokines and soluble HLA-G levels in children with leukemia who undergo allogeneic stem cell transplantation


KAYA Z., YÜCE D. , KİRKİZ KAYALI S., KOÇAK Ü., Ozmen F.

CYTOKINE, vol.153, 2022 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 153
  • Publication Date: 2022
  • Doi Number: 10.1016/j.cyto.2022.155869
  • Title of Journal : CYTOKINE
  • Keywords: Cytokines, soluble HLA-G, Pediatric leukemia, Transplantation, ACUTE LYMPHOBLASTIC-LEUKEMIA, VERSUS-HOST-DISEASE, ACUTE MYELOID-LEUKEMIA, NECROSIS-FACTOR-ALPHA, TURKISH CHILDREN, GENE-EXPRESSION, COMPLICATIONS, SEVERITY, RECEPTOR

Abstract

This is the first study to have investigated the prognostic role of cytokines and soluble human leukocyte antigen -G (sHLA-G) levels in pediatric leukemia patients who have undergone allogeneic stem cell transplantation (allo-SCT). Forty-one patients with acute leukemia (n = 28, acute lymphoblastic leukemia (ALL) and n = 13, acute myeloblastic leukemia) were recruited. Patients were examined at diagnosis (n = 26), in the pre-transplantation period (PreTx) (n = 26), on the day of transplantation (Tx(0)) (n = 41), and on post-transplantation Days 14 (PostTx(14)) (n = 41) and 28 (PostTx(28)) (n = 41). Serum levels of pro-inflammatory cytokines (interleukin [IL]-1, IL-2, IL-6, Tumor necrosis factor [TNF]-alpha), anti-inflammatory cytokines (IL-4, IL-10), and sHLA-G were measured by Enzyme-Linked ImmunoSorbent Assay. Median levels of all cytokines tested and sHLA-G were significantly higher at diagnosis and at the post-transplant time points than at PreTx (all p < 0.05). At the time of diagnosis (specifically ALL) and at PostTx(14), elevated IL-4, IL-10, and/or sHLA-G were associated with higher post-transplant relapse rates (all p < 0.05). Elevated IL-2 and TNF-alpha at Tx(0) were associated with lower survival rates (both p < 0.05). Levels of serum cytokines and sHLA-G may be useful predictors of survival and relapse in pediatric leukemia patients who undergo allo-SCT.